The macula is the central part of the retina. It allows you to read, recognise faces, drive and see fine details. When damaged retinal blood vessels leak fluid, the macula becomes thickened or develops small fluid-filled spaces. This swelling is called macular edema.

A simple analogy is a camera sensor becoming waterlogged at its most important central point. Peripheral vision may remain relatively normal, while the centre becomes blurred, distorted or washed out. Chronic swelling can injure light-sensitive retinal cells, which is why timely diagnosis and appropriate follow-up matter.

Macular edema is not the same as macular degeneration. However, wet age-related macular degeneration may also produce fluid in or under the macula and requires a different diagnostic and treatment framework.

The cause must be identified before treatment begins

The same OCT finding can result from diabetes, a blocked retinal vein, inflammation, recent cataract surgery, vitreomacular traction or another retinal disorder. Treatment is therefore selected for the diagnosis—not merely for the presence of fluid.

Second opinions are welcome. Bring previous OCT scans, angiography reports, injection records and systemic medical reports.

Early or mild macular edema may cause no obvious symptom and may be detected during diabetic retinal screening. When symptoms are present, one or both eyes may be affected.

• Blurred or hazy central vision
• Straight lines appearing bent or wavy
• Difficulty reading small print
• Reduced contrast or washed-out colours
• A grey, dull or missing patch in central vision
• Different image size between the two eyes
• Difficulty recognising faces or seeing fine detail
• Vision that fluctuates with blood glucose changes

Symptoms alone cannot measure the severity. Some patients have significant OCT swelling with good reading vision, while others experience major visual difficulty with relatively modest thickening because the central photoreceptors have been affected.

The underlying cause determines whether the best option is observation, an eye injection, topical medication, steroid treatment, retinal laser, systemic therapy or surgery. A treatment that is appropriate for diabetic macular edema may be unsuitable for infectious or tractional disease.

The evaluation begins with visual acuity, eye pressure, slit-lamp examination and pupil dilation. The retina is then examined to assess haemorrhages, hard exudates, vascular changes, inflammation, traction and the condition of the optic nerve.

Optical coherence tomography (OCT) is the principal imaging test for most patients. OCT is painless, non-contact and provides cross-sectional retinal images. However, the scan must be interpreted together with vision, symptoms and the clinical examination; a single thickness number should not determine treatment.

Fundus photography, OCT-angiography or fluorescein angiography may be advised when the leakage source, retinal blood flow or neovascularisation requires further evaluation. An ocular ultrasound is useful when cataract or vitreous haemorrhage prevents a clear retinal view.

Diagnosis is more than “fluid present” or “fluid absent”

Dr. Gala reviews whether the edema involves the foveal centre, whether visual acuity is affected, whether traction is present, and whether the condition is active, chronic or improving. These details determine when to treat and how closely to monitor.

The SV Road clinic is convenient for patients from DN Nagar, Lokhandwala, Oshiwara, Versova, Four Bungalows, Seven Bungalows, Juhu and Andheri Railway Station.

There is no single injection schedule or treatment that is correct for every patient. The plan considers the cause, visual acuity, OCT pattern, lens status, eye pressure, pregnancy status, previous response, systemic health and ability to attend follow-up visits.

Vascular endothelial growth factor, or VEGF, increases vascular leakage and abnormal vessel growth. Anti-VEGF medicines reduce this signalling and are commonly used for center-involving diabetic macular edema with visual impairment and macular edema caused by retinal vein occlusion.

Examples include aflibercept, ranibizumab, bevacizumab and other agents selected according to diagnosis, availability, previous response, cost and regulatory status. Bevacizumab is used off-label in ophthalmology in many settings; this should be discussed before treatment.

In the DRCR Retina Network’s comparative randomised trial, aflibercept, bevacizumab and ranibizumab all improved vision in center-involving diabetic macular edema, while average differences depended on the starting level of visual acuity. Read the original Protocol T trial in the New England Journal of Medicine.

Another randomised trial found that selected patients with center-involving diabetic macular edema and good visual acuity could be initially observed, with aflibercept started if vision worsened, rather than receiving automatic immediate injections. Read the original DRCR Protocol V trial.

Intravitreal steroid treatment

Steroid injections or implants may be considered for inflammatory macular edema, selected diabetic macular edema, pseudophakic eyes or edema that has responded inadequately to other treatment. Steroids can raise eye pressure and accelerate cataract, so glaucoma risk and lens status must be considered.

Focal or grid retinal laser

Laser is no longer the default treatment for all center-involving DME with visual loss, but it remains useful in selected non-central leakage patterns and as an adjunct. The landmark Early Treatment Diabetic Retinopathy Study showed that focal photocoagulation reduced the risk of visual loss in clinically significant diabetic macular edema under the treatment framework used at that time. View the original ETDRS macular edema report.

Post-cataract cystoid macular edema

Mild postoperative edema may be treated initially with anti-inflammatory eye drops, commonly a corticosteroid and/or non-steroidal anti-inflammatory medicine. Persistent or severe cases may need periocular or intravitreal therapy after infection, retinal vein occlusion, diabetes and traction have been excluded.

Most macular edema is treated medically rather than surgically. Vitrectomy is considered when the vitreous or an epiretinal membrane is pulling on the macula, when non-clearing vitreous haemorrhage prevents treatment, or when another surgical retinal condition is present.

During surgery, the vitreous gel is removed. If indicated, Dr. Gala may peel an epiretinal membrane and the internal limiting membrane to relieve traction. Laser, gas or other steps may be added according to the retinal findings.

Surgery removes mechanical traction but does not automatically eliminate leakage caused by diabetes or vascular disease. Some eyes still need injections, laser or systemic control after vitrectomy.

Learn more about vitreoretinal treatment by Dr. Jignesh Gala and retina services at Crystal Clear Eye Clinic.

Intravitreal injections are usually performed as a short sterile procedure. The injection itself takes only moments, although preparation and post-procedure checks require additional time.

Mild grittiness, watering, a red spot on the white of the eye or temporary floaters can occur. Severe pain, increasing redness, marked light sensitivity or worsening vision may indicate infection or another complication and requires immediate contact with the treating eye surgeon.

Eye treatment addresses retinal leakage, but systemic disease influences recurrence and long-term retinal health. Patients with diabetic macular edema should work with their physician or diabetologist on glucose, blood pressure, cholesterol, kidney disease, anaemia, smoking and sleep-related conditions.

• Know your recent HbA1c and glucose trend
• Maintain blood pressure targets advised by your physician
• Review kidney function and urine protein when appropriate
• Take prescribed diabetes and cardiovascular medicines consistently
• Stop smoking and address obesity or sedentary lifestyle
• Continue eye follow-up even when vision temporarily improves

Rapid, major changes in blood glucose can temporarily alter vision and refraction. However, persistent central blur or OCT edema should not be attributed to spectacle power without a retinal evaluation.

The cost depends on the cause, required scans, injection medicine, number of treatments, laser plan and whether surgery is needed. A consultation and OCT-based assessment are required before an accurate treatment estimate can be provided.

• Transparent discussion before tests and procedures
• Different injection options explained where clinically appropriate
• 30+ cashless TPA and insurance tie-ups, subject to approval
• EMI or financing options for eligible procedures
• Written estimate when a procedure or surgery is advised
• No guarantee that every insurer covers every injection or indication

Review the clinic’s cashless and insurance information and confirm policy eligibility with your insurer or TPA.